FG300 Multirole Programmable AC Microcurrent

PAIN TREATMENT AND INJURED TISSUE HEALING







HOW IT WORKS: INTRACELLULAR SECOND MESSENGER STIMULATION TECHNOLOGY



  • Second messengers are molecules that relay the original, first signals received at receptors on the surface of a cell, to target molecules inside the cell. The first messengers that reach the cell are the extracellular signaling factors such as hormones and neurotransmitters including epinephrine and serotonin, that trigger the cell to take specific action(s).

  • A key feature of the second messenger signaling system is that it amplifies the original signals.

  • The FG300 can precisely target electrical stimulation to both the important cyclic-AMP (cAMP) and cyclic-GMP (cGMP) second messengers.



TWO TYPES OF PAIN

  • Nociceptive type pain occurs when specialized sensory neurons called nociceptors, signal along axon nerve fibres to the brain that injury exists or that there is danger of injury to tissues of the body. The pain signals start from the inside-to-outside voltage-gated ion channels through the walls of the nociceptor neurons.

  • Neuropathic type pain (neuropathy) is caused by damage to nerves themselves from trauma injury, surgery, disease or chemotherapy, so that they no longer function correctly.



Nociceptive type pain signals transmitted from peripheral sensory neurons to the spinal cord and brain




Neuropathic damaged nerve axon fibers (red) within a nerve bundle are therapeutic targets for cyclic-AMP mediated regeneration


  • Increasing cAMP activity directly affects the pain neuron.

    The targeted electrical stimulation does not 'cover-up' the natural pain generating process. The FG300 can be programmed to directly modulate the cAMP signal transduction pathway, with the result of decreasing the overall activity and the specific electrical voltage across nociceptor neuron wall ion channels—reducing or stopping the transmission of pain signals.

    In addition, favourably modulating cAMP has strong regenerative effects on damaged peripheral nerve tissue (neuropathy).

    These effects have been extensively studied from chemical-based cAMP intervention. The FG300 technology is the first targeted programmable electromedical approach that can achieve this result. Supporting research>




CYCLIC-AMP STIMULATION TECHNOLOGY

  • Cyclic-A-M-P is produced within cells from the A-T-P molecule. A-T-P is the 'energy currency' of life, it functions like a rechargeable battery, and is the energy source that all cells need in order to do any work. In response to injury, A-T-P (ATP) is converted repeatedly into cyclic-A-M-P (cAMP). The cAMP molecules then relay the specific messages to carry out the healing processes for the injury.

    The FG300 can precisely target and modulate up or down the production and utilization of the cAMP second messenger molecule and activation pathway. The targeted electrical stimulation does not 'cover-up' the natural pain generating process. The FG300 can be programmed to directly modulate the cAMP signal transduction pathway, with the result of decreasing the overall activity and the specific electrical voltage across nociceptor neuron wall ion channels—reducing or stopping the transmission of pain signals.

    In addition, favourably modulating cAMP has strong regenerative effects on damaged peripheral nerve tissue (neuropathy).

    These effects have been extensively studied from chemical-based cAMP intervention. The FG300 technology is the first targeted programmable electromedical approach that can achieve this result. Supporting research>




Cyclic-AMP (cAMP) second messenger activation and effects in response to injury





CYCLIC-GMP STIMULATION TECHNOLOGY

  • The cyclic-GMP (cGMP) second messenger relays and amplifies signals that increases the mobilization of energy resources by up-regulating the glucose metabolism pathway in muscles around the injury. The increase in available energy accelerates injury healing. cGMP also enhances cell migration including stem cells to injured tissues such as wounds, and has angiogenesis (regeneration of blood vessel) stimulating effects. Supporting research>

    The FG300 can precisely target and modulate up or down the production and utilization of the cGMP second messenger molecule and activation pathway.




FG300 TECHNOLOGY: DEVELOPMENT

  • The FG300 technology has been developed from special cooperation between American Physiatrist (pain and injury rehabilitation specialist physician) and scientist, Doctor James Woessner MD PhD, and the Electromedicine Clinic in Melbourne, Australia. Doctor Woessner has pioneered and performed around 4000 non-invasive electrical nerve block treatments, which he recognized were simultaneously actually repairing damaged pain nerves, probably via cAMP activation. Vita of Dr James Woessner>

    The FG300 is the result of data based development in parallel with laboratory equipment validation and clinical testing.

    The FG300 has been designed for use by both clinicians and at home.



ELECTROTHERAPY: CHALLENGES FOR INJURY TREATMENTS

  • The healing process in response to an injury is fantastically complex, involving millions of cells. Each cell performs a unique and specialized function in the effort to repair and regenerate the injured tissues, in moment-by-moment constantly changing coordination with every other cell.

    We cannot know what each cell involved in the healing process is doing at any time: trillions of chemical reactions happen in the body every second—most remain unknown to medical science. This makes appropriate electrical stimulation very hard to determine.


  • No two injuries are the same. Every injury, even of the same anatomical structure, is a unique occurrence in each individual, requiring their body's precisely coordinated, unique healing response.

    Most electrotherapy devices for injury and pain treatments, transmit waveforms and frequencies into the body, in a non-targeted, 'blanket' bombardment of electrical stimulation (energy). Some cellular metabolic activities can be temporarily enhanced as a result, while other cellular processess can be negatively interfered with or completely inhibited.

    The FG300 second messenger stimulation technology solves these electrotherapy challenges by directly targeting and boosting what the body is already doing via precise stimulation of the second messenger signaling system that accelerates healing and regeneration of the damaged tissues (the injury).


CYCLIC-AMP AND CYCLIC-GMP STIMULATION EFFECTS

  • Pain neuron (nociceptor) blockade—cAMP directly affects the pain nerve cell (neuron) wall voltage-gated ion channels, so that neuropathic pain signals reduce or stop.


  • Relays and greatly amplifies the first messages to begin and continue the metabolic activity for healing—including genetic expression.


  • Increases neuron and axon (sensing and movement signal conductors) survival and regeneration following injury.


  • Immune and non-immune system anti-inflammatory effects, giving immediate and long term injured tissue protection.


  • Circulation enhancement—induces and enhances localized vascular relaxation.


  • Reduces muscle tension and exerts central nervous system antispastic actions after injury.


  • Enhances the effects of functional stimulation and regeneration of muscles and nerves following injury.


  • Enhances angiogenesis in injured tissues (regeneration of new blood vessels).


  • Increases mobilization of energy resources via the carbohydrate metabolism pathway and accelerates tissue healing.


NEW PAIN & INJURY TREATMENT

  • Enhanced and faster injury healing. Targeted signaling stimulation of intracellular second messenger cyclic-A-M-P and cyclic-G-M-P molecule pathways that relay and amplify the messages for metabolic activity and healing.

  • Neuropathic pain blocking. Decreases the overall activity, and the 'action potential' electrical voltage, of pain nerve cell voltage-gated ion channels, reducing or stopping the transmission of pain signals.

  • Increased nerve cell (neuron) and axon survival and regeneration after injury. Prevention of future neuropathic pain and loss of function.

  • Anti-inflammatory. Modulates both immune and non-immune system inflammatory processes—protects injured tissues from chronic degradation.

  • Enhances circulation. Relaxes localized small blood vessels (vasodilation).

  • Reduces muscle tension. Enhances function and regeneration of muscles and nerves following injury.

  • Increases localized carbohydrate metabolism. Increased energy accelerates tissue healing.

  • Non-invasive and no drug side effects. For home and clinic use.

  • International Patent Application Pending device & technology.

CONTACT US